Taken together, RNLS should be considered in the analysis of BCR-ABL1-related mechanisms in the development and maintenance of CML, as well as management strategies that aim to overcome TKI resistance and CML progression. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.